Videos

Stage IIIA Unresectable NSCLC After Chemoradiotherapy

Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.

A 75-Year-Old Man With Right-Sided mCRC

KRAS-Mutated Metastatic CRC

Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.

Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.

Tanya Dorff, MD, discusses recent data with olaparib (Lynparza) in castration-resistant prostate cancer and the future role of PARP inhibitors in this disease.<br /> &nbsp;

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

Lung Cancer

Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.

Josep M. Llovet, MD, PhD, discussed the available treatment options for patients with hepatocellular carcinoma.

<br /> &#8203;Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.